Trial · NCT02251613
Effectiveness of Olopatadine HCl Ophthalmic Solution for the Treatment of Allergic Conjunctivitis in Japan
NCT02251613, Phase 4, Completed, Alcon Research; results first posted 2015-02-09
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effectiveness of Olopatadine HCl Ophthalmic Solution for the Treatment of Allergic Conjunctivitis in Japan. Trials, record NCT02251613. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02251613
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effectiveness of Olopatadine HCl Ophthalmic Solution for the Treatment of Allergic Conjunctivitis in Japan
- NCT number
- NCT02251613
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 50 participants, actual
- Lead sponsor
- Alcon Research
- Conditions
- Allergic Conjunctivitis
- Interventions
- Olopatadine HCl ophthalmic solution, 0.1%, Epinastine HCl ophthalmic solution, 0.05%
- First posted
- 2014-09-29
- Last updated
- 2015-10-07
- Results first posted
- 2015-02-09
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Mean Ocular Itching at 7 Minutes Post-CAC, Day 1 | Day 1, 7 minutes post-CAC | A CAC (one drop of allergen solution to each eye) was performed 5 minutes after study medication instillation. Ocular itching was assessed by the patient for each eye at 7 (±1) minutes post-CAC and rated on a 0-4 scale (0=none, 4=incapacitating itch with irresistible urge to rub). |
| Secondary | Mean Conjunctival Hyperemia at 20 Minutes Post-CAC, Day 1 | Day 1, 20 minutes post-CAC | A CAC (one drop of allergen solution to each eye) was performed 5 minutes after study medication instillation. Conjunctival hyperemia (redness) was evaluated by the investigator based on biomicroscopy for each eye at 20 (±1) minutes post-CAC and rated on a 0-4 scale (0=none, 4=extremely severe). |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Mean Ocular Itching at 7 Minutes Post-CAC, Day 1 | Day 1, 7 minutes post-CAC | This analysis population includes all randomized participants. | units on a scale | MEAN |
| SECONDARY | Mean Conjunctival Hyperemia at 20 Minutes Post-CAC, Day 1 | Day 1, 20 minutes post-CAC | This analysis population includes all randomized participants. | units on a scale | MEAN |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Mean Ocular Itching at 7 Minutes Post-CAC, Day 1 | Olopatadine 0.1% | 0.23 | Standard Deviation 0.31 | units on a scale | |
| Mean Ocular Itching at 7 Minutes Post-CAC, Day 1 | Epinastine 0.05% | 0.37 | Standard Deviation 0.44 | units on a scale | |
| Mean Conjunctival Hyperemia at 20 Minutes Post-CAC, Day 1 | Olopatadine 0.1% | 0.89 | Standard Deviation 0.88 | units on a scale | |
| Mean Conjunctival Hyperemia at 20 Minutes Post-CAC, Day 1 | Epinastine 0.05% | 1.12 | Standard Deviation 0.95 | units on a scale |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Overall | 50 | |
| Overall Study | COMPLETED | Overall | 50 | |
| Overall Study | NOT COMPLETED | Overall | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Olopatadine 0.1% | ||
| Total, all-cause mortality | Epinastine 0.05% | ||
| Total, other adverse events | Olopatadine 0.1% | 0 | 50 |
| Total, other adverse events | Epinastine 0.05% | 0 | 50 |
| Total, serious adverse events | Olopatadine 0.1% | 0 | 50 |
| Total, serious adverse events | Epinastine 0.05% | 0 | 50 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Olopatadine 0.1% vs Epinastine 0.05%: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02251613
GET https://conductscience.org/api/trials/v1/NCT02251613/registered